PDCD1 and melanoma: Based on the above results of CRABP2 on the prediction of efficacy and prognosis in immunotherapy, we found that in melanoma, the high expression of CRABP2 may be related to the downregulation of checkpoint molecules, contributing to non-response and poor-prognosis to PD-1 treatment.